Investigational drug · Phase 3
Tetravalent Inactivated Enterovirus Vaccine
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Herpangina, Hand, Foot, and Mouth Disease(HFMD), Hand, Foot, and Mouth Disease (HFMD).
Phase 3Last checked: Nov 20, 2026Latest source record: May 28, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
1 still active
All registered trials
2
Any phase or sponsor naming "Tetravalent Inactivated Enterovirus Vaccine"
First trial start
2025
Jan 15, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Tetravalent Inactivated Enterovirus Vaccine", any sponsor or status.
Conditions studied
As listed on its trial records.
- Herpangina
- Hand, Foot, and Mouth Disease(HFMD)
- Hand, Foot, and Mouth Disease (HFMD)
Largest trials
Live from ClinicalTrials.gov: studies naming "Tetravalent Inactivated Enterovirus Vaccine" as an intervention, largest first.
- Protective Efficacy , Immunogenicity and Safety of the Tetravalent Inactivated Enterovirus Vaccine (Vero Cell).Pivotal-lookingNot yet recruiting
Sinovac Biotech Co., LtdIndustry
NCT07611513 · 6,000 participants (planned) · Start May 2026 · Primary completion Dec 2027
Drug: Tetravalent Inactivated Enterovirus Vaccine (Vero Cell); Placebo · For: Hand, Foot, and Mouth Disease(HFMD); Herpangina
Sites: Hefei, China; Fujian, China; Henan, China · 5 sites in all
- Tolerability, Safety, and Immunogenicity of Tetravalent Inactivated Enterovirus Vaccine (Vero Cell).Pivotal-lookingCompleted
Sinovac Biotech Co., LtdIndustry
NCT06754384 · 552 participants · Start Jan 15, 2025 · Primary completion Dec 30, 2025
Drug: Low-dose of tetravalent inactivated enterovirus vaccine (Vero cell); Medium-dose tetravalent inactivated enterovirus vaccine (Vero cell) and 3 more · For: Hand, Foot, and Mouth Disease (HFMD); Herpangina
Sites: Hangzhou, China
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Herpangina
- bivalent enterovirus vaccinePhase 32 trials
Sinovac Biotech Co., Ltd · Hand, Foot, and Mouth Disease(HFMD), Hand, Foot and Mouth Disease, Herpangina
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.